RecruitingPhase 4NCT06971939
Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure Participants
Studying Rare idiopathic macular telangiectasia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Neurotech Pharmaceuticals
- Principal Investigator
- Thomas Aaberg, Jr, MDNeurotech Pharmaceuticals
- Intervention
- NT-501/revakinagene taroretcel-lwey(combination_product)
- Enrollment
- 285 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2030
Study locations (30)
- Scripps Health, La Jolla, California, United States
- Jules Stein Eye Institute/UCLA, Los Angeles, California, United States
- Stanford University School of Medicine, Palo Alto, California, United States
- Bay Area Retina Associates, Walnut Creek, California, United States
- Emory Eye Center, Atlanta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- Elman Retina Group, PA, Baltimore, Maryland, United States
- National Eye Institute, Bethesda, Maryland, United States
- Cumberland Valley Retina Consultants, Frederick, Maryland, United States
- Massachusetts Eye and Ear Infirmary, Retina Service, Boston, Massachusetts, United States
- Foundation for Vision Research, Grand Rapids, Michigan, United States
- Mayo Clinic, Rochester, Minnesota, United States
- The Retina Institute, St Louis, Missouri, United States
- Envision Ocular, LLC, Bloomfield, New Jersey, United States
- Cincinnati Eye Institute, Cincinnati, Ohio, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06971939 on ClinicalTrials.gov